Dashboard

AstraZeneca PLC

AZNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$263B

Price$169.2652w $68.72 – $209.48

Conviction4/ 5

Revenue (TTM)$60.4B

Revenue growth YoY+9.9%

P/E (trailing)25.3

Gross margin81.7%

Operating margin23.7%

Net margin17.2%

52w price change+131.8%

Next earningsJul 27, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Jul 23
RegulatorySEC
6-K reports EU approval of Ectamah for ER+ breast cancer
Jul 14
DealSEC
AstraZeneca licenses novel EGFR inhibitor (6-K filing).
Jul 9
Trial readoutSEC
6-K filing: update on Cardio-TTransform Phase III trial.
Jul 8
Ownership changeSEC
Form 4 insider ownership filing
Jul 1
Securities offeringSEC
AstraZeneca 6-K reports admission of further securities to trading.
Jul 1
OtherSEC
AstraZeneca files 6-K disclosing total voting rights.
Jun 29
RegulatorySEC
EU approval of Enhertu for HER2+ solid tumors
Jun 29
RegulatorySEC
DATROWAY recommended for approval in EU for TNBC
Jun 16
Ownership changeSEC
SEC Form 4 ownership document filed for AZN insider transaction.
Jun 15
RegulatorySEC
Truqap approved in the US for prostate cancer per 6-K filing.
Jun 2
Trial initiationClinicalTrials.gov
AstraZeneca Phase 3 trial NCT07430306 (subcutaneous anifrolumab in immunosuppressant- and biologic-naïve SLE) status updated to RECRUITING
Jun 1
Securities offeringSEC
6-K filing on admission of further securities to trading.
Jun 1
OtherSEC
AstraZeneca 6-K reports total voting rights as of 2026-06-01.
May 29
RegulatorySEC
Imfinzi approved in US for early bladder cancer
May 27
PDUFASEC
6-K reports US FDA decision date on Camizestrant extended.
May 26
Trial initiationClinicalTrials.gov
AstraZeneca initiates recruiting non-interventional study NCT06465810 in ATTR amyloidosis
May 26
RegulatorySEC
US approval of Datroway for 1L triple-negative breast cancer reported via 6-K.
May 26
RegulatorySEC
ENHERTU recommended in EU for HER2+ solid tumours
May 26
RegulatorySEC
Camizestrant recommended for breast cancer treatment in EU (6-K).
May 22
Ownership changeSEC
SEC Form 4 ownership document filed.

Not financial advice — research and opinion only. Disclosures